Compare CALX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALX | TRVI |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2009 | 2019 |
| Metric | CALX | TRVI |
|---|---|---|
| Price | $36.71 | $13.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $62.33 | $28.18 |
| AVG Volume (30 Days) | 917.3K | ★ 2.6M |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | 31.91 |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $510,367,000.00 | N/A |
| Revenue This Year | $19.15 | N/A |
| Revenue Next Year | $15.63 | N/A |
| P/E Ratio | $90.89 | ★ N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $32.35 | $9.82 |
| 52 Week High | $69.73 | $20.22 |
| Indicator | CALX | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 49.73 |
| Support Level | $34.70 | $13.08 |
| Resistance Level | $41.02 | $13.55 |
| Average True Range (ATR) | 1.10 | 0.60 |
| MACD | 0.16 | 0.27 |
| Stochastic Oscillator | 43.84 | 76.06 |
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Europe, Americas excluding U.S., and Rest of World.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.